<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Merck Kgaa — News on 6ix</title>
<link>https://6ix.com/company/merck-kgaa</link>
<description>Latest news and press releases for Merck Kgaa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/merck-kgaa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836069778dffbe2df136684.webp</url>
<title>Merck Kgaa</title>
<link>https://6ix.com/company/merck-kgaa</link>
</image>
<item>
<title>Remepy Announces Collaboration with Merck KGaA, Darmstadt Germany to Advance Hybrid Drugs Across Therapeutic Areas</title>
<link>https://6ix.com/company/merck-kgaa/news/remepy-announces-collaboration-with-merck-kgaa-darmstadt-germany-to-advance-hybrid-drugs-across-therapeutic-areas</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/remepy-announces-collaboration-with-merck-kgaa-darmstadt-germany-to-advance-hybrid-drugs-across-therapeutic-areas</guid>
<pubDate>Tue, 28 Apr 2026 11:00:00 GMT</pubDate>
<description>Remepy, the pioneer of Hybrid Drugs, today announced a collaboration with Merck KGaA, Darmstadt Germany, a leading science and technology company, to explore the development of Hybrid Drugs across multiple therapeutic areas.</description>
</item>
<item>
<title>MilliporeSigma Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography</title>
<link>https://6ix.com/company/merck-kgaa/news/milliporesigma-launches-first-bio-based-solvent-portfolio-for-high-performance-liquid-chromatography</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/milliporesigma-launches-first-bio-based-solvent-portfolio-for-high-performance-liquid-chromatography</guid>
<pubDate>Tue, 21 Apr 2026 12:00:00 GMT</pubDate>
<description>HPLC Bio-Based Solvents MilliporeSigma recently launched a line-up of patent-pending bio-based solvents for HPLC. Made from renewable feedstocks, these innovative drop-in replacements – designed to work in existing HPLC methods, thus eliminating the lengthy process of redeveloping analytical methods – can help reduce reliance on fossil-based materials. Burlington, Massachusetts, April 21, 2026 (GLOBE NEWSWIRE) -- Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based m</description>
</item>
<item>
<title>MilliporeSigma Completes Acquisition of JSR Life Sciences’ Chromatography Business, Expanding Protein A Capabilities and Downstream Portfolio</title>
<link>https://6ix.com/company/merck-kgaa/news/milliporesigma-completes-acquisition-of-jsr-life-sciences-chromatography-business-expanding-protein-a-capabilities-and-downstream-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/milliporesigma-completes-acquisition-of-jsr-life-sciences-chromatography-business-expanding-protein-a-capabilities-and-downstream-portfolio</guid>
<pubDate>Wed, 01 Apr 2026 12:00:00 GMT</pubDate>
<description>MilliporeSigma Completes Acquisition of JSR Life Sciences’ Chromatography Business MilliporeSigma Completes Acquisition of JSR Life Sciences’ Chromatography Business Burlington, Massachusetts, April 01, 2026 (GLOBE NEWSWIRE) -- Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturingIntegrated downstream workflows to improve productivity and help speed access to critical therapies MilliporeSigma, the U.S. and Canada Life Science business</description>
</item>
<item>
<title>EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities</title>
<link>https://6ix.com/company/merck-kgaa/news/emd-serono-advances-patient-access-to-ivf-medicines-in-the-us-aligned-with-national-health-priorities</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/emd-serono-advances-patient-access-to-ivf-medicines-in-the-us-aligned-with-national-health-priorities</guid>
<pubDate>Fri, 06 Feb 2026 13:00:00 GMT</pubDate>
<description>BOSTON, February 06, 2026--EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, in collaboration with President Trump’s administration, announced new patient access pathways to make its complete portfolio of infertility medications used for in vitro fertilization (IVF), including Gonal-f® (follitropin alfa for injection), Ovidrel® (choriogonadotropin alfa injection), and Cetrotide® (cetrorelix acetate for injection), more accessible to prescribed infertil</description>
</item>
<item>
<title>Merck and ChemLex Sign Memorandum of Understanding to Advance Automated Chemistry and Technological Innovation</title>
<link>https://6ix.com/company/merck-kgaa/news/merck-chemlex-sign-memorandum-understanding-081600913</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/merck-chemlex-sign-memorandum-understanding-081600913</guid>
<pubDate>Tue, 20 Jan 2026 08:16:00 GMT</pubDate>
<description>Merck, a leading science and technology company, and ChemLex, a Singapore-headquartered innovation company pioneering AI-driven automated chemical synthesis, today announced the signing of a Memorandum of Understanding (MOU) to explore a strategic collaboration in evolving R&D paradigms.</description>
</item>
<item>
<title>FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor</title>
<link>https://6ix.com/company/merck-kgaa/news/fda-accepts-new-drug-application-for-pimicotinib-for-the-treatment-of-tenosynovial-giant-cell-tumor</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/fda-accepts-new-drug-application-for-pimicotinib-for-the-treatment-of-tenosynovial-giant-cell-tumor</guid>
<pubDate>Mon, 12 Jan 2026 19:00:00 GMT</pubDate>
<description>BOSTON, January 12, 2026--FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor</description>
</item>
<item>
<title>Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor</title>
<link>https://6ix.com/company/merck-kgaa/news/abbisko-therapeutics-csf-1r-inhibitor-pimicotinib-approved-by-the-china-nmpa-addressing-the-treatment-gap-for-tenosynovial-giant-cell-tumor-1</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/abbisko-therapeutics-csf-1r-inhibitor-pimicotinib-approved-by-the-china-nmpa-addressing-the-treatment-gap-for-tenosynovial-giant-cell-tumor-1</guid>
<pubDate>Mon, 22 Dec 2025 11:29:00 GMT</pubDate>
<description>Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the world’s first regulatory approval for pimicotinib, the first domestically developed systemic therapy for the treatment of Tenosynovial Giant Cell Tumor (TGCT), to our partner Merck KGaA, Darmstadt, Germany, which holds worldwide commercialization rightsPimicotinib, a Class 1 innovative drug discovered and developed by Abbisko Therapeutics, received zero-deficiency approval i</description>
</item>
<item>
<title>Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson’s Disease and Related Disorders</title>
<link>https://6ix.com/company/merck-kgaa/news/valo-health-announces-collaboration-with-merck-kgaa-darmstadt-germany-to-discover-and-develop-novel-treatments-for-parkinsons-disease-and-related-disorders</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/valo-health-announces-collaboration-with-merck-kgaa-darmstadt-germany-to-discover-and-develop-novel-treatments-for-parkinsons-disease-and-related-disorders</guid>
<pubDate>Thu, 20 Nov 2025 11:30:00 GMT</pubDate>
<description>LEXINGTON, Mass., November 20, 2025--Valo Health announces collaboration with Merck KGaA, Darmstadt, Germany to discover and develop novel treatments for Parkinson’s and related disorders</description>
</item>
<item>
<title>Universal Display Corporation to Acquire Emissive OLED Patent Assets from Merck KGaA, Darmstadt, Germany</title>
<link>https://6ix.com/company/merck-kgaa/news/universal-display-corporation-to-acquire-emissive-oled-patent-assets-from-merck-kgaa-darmstadt-germany</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/universal-display-corporation-to-acquire-emissive-oled-patent-assets-from-merck-kgaa-darmstadt-germany</guid>
<pubDate>Thu, 06 Nov 2025 21:15:00 GMT</pubDate>
<description>EWING, N.J., November 06, 2025--UDC today announced that it has entered into a definitive agreement to acquire OLED patent assets from Merck KGaA, Darmstadt, Germany.</description>
</item>
<item>
<title>Merck KGaA, Darmstadt, Germany Signs Long-Term Renewable Energy Contract for South Korea Sites</title>
<link>https://6ix.com/company/merck-kgaa/news/merck-kgaa-darmstadt-germany-signs-long-term-renewable-energy-contract-for-south-korea-sites</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/merck-kgaa-darmstadt-germany-signs-long-term-renewable-energy-contract-for-south-korea-sites</guid>
<pubDate>Tue, 04 Nov 2025 14:00:00 GMT</pubDate>
<description>20-year Power Purchase Agreement with SK Innovation E&S to add 16 MW of renewable electricity capacity starting in December 2027 Supports company's 2030 sustainability targets to source 80% renewable electricity and reduce Scope 1 and 2 emissions ...</description>
</item>
<item>
<title>MilliporeSigma Partners with Promega to Advance 3-D Cell Drug Discovery Technologies</title>
<link>https://6ix.com/company/merck-kgaa/news/milliporesigma-partners-with-promega-to-advance-3-d-cell-drug-discovery-technologies</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/milliporesigma-partners-with-promega-to-advance-3-d-cell-drug-discovery-technologies</guid>
<pubDate>Tue, 28 Oct 2025 12:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., October 28, 2025--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin, to co-develop novel technologies that advance drug screening and discovery.</description>
</item>
<item>
<title>SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology</title>
<link>https://6ix.com/company/merck-kgaa/news/springworks-therapeutics-announces-publication-of-long-term-efficacy-and-safety-data-from-the-phase-3-defi-trial-of-ogsiveor-nirogacestat-in-adults-with-desmoid-tumors-in-the-journal-of-clinical-oncology</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/springworks-therapeutics-announces-publication-of-long-term-efficacy-and-safety-data-from-the-phase-3-defi-trial-of-ogsiveor-nirogacestat-in-adults-with-desmoid-tumors-in-the-journal-of-clinical-oncology</guid>
<pubDate>Tue, 21 Oct 2025 06:00:00 GMT</pubDate>
<description>Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profileSTAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inh</description>
</item>
<item>
<title>EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies</title>
<link>https://6ix.com/company/merck-kgaa/news/emd-serono-announces-unprecedented-agreement-with-us-government-to-expand-access-to-ivf-therapies</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/emd-serono-announces-unprecedented-agreement-with-us-government-to-expand-access-to-ivf-therapies</guid>
<pubDate>Thu, 16 Oct 2025 19:51:00 GMT</pubDate>
<description>BOSTON, October 16, 2025--EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, and President Donald J. Trump’s administration, today announced an agreement to expand access to the company’s portfolio of in vitro fertilization (IVF) therapies for the more than 10 million American women struggling to have a baby.</description>
</item>
<item>
<title>MilliporeSigma to Acquire Chromatography Business of JSR Life Sciences, Expanding Protein A Capabilities and Downstream Portfolio</title>
<link>https://6ix.com/company/merck-kgaa/news/milliporesigma-to-acquire-chromatography-business-of-jsr-life-sciences-expanding-protein-a-capabilities-and-downstream-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/milliporesigma-to-acquire-chromatography-business-of-jsr-life-sciences-expanding-protein-a-capabilities-and-downstream-portfolio</guid>
<pubDate>Wed, 15 Oct 2025 13:03:00 GMT</pubDate>
<description>BURLINGTON, Mass., October 15, 2025--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Life Science business of Merck KGaA, Darmstadt, Germany has signed a definitive agreement to acquire the chromatography business of JSR Life Sciences, a leader in contract development and manufacturing, preclinical and translational clinical research, and bioprocessing solutions. The acquisition will e</description>
</item>
<item>
<title>Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions</title>
<link>https://6ix.com/company/merck-kgaa/news/biocytogen-enters-into-agreement-with-merck-kgaa-darmstadt-germany-to-advance-antibody-conjugated-lipid-based-delivery-solutions</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/biocytogen-enters-into-agreement-with-merck-kgaa-darmstadt-germany-to-advance-antibody-conjugated-lipid-based-delivery-solutions</guid>
<pubDate>Thu, 04 Sep 2025 00:00:00 GMT</pubDate>
<description>BEIJING, September 04, 2025--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated</description>
</item>
<item>
<title>Merck KGaA, Darmstadt, Germany, Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector</title>
<link>https://6ix.com/company/merck-kgaa/news/merck-kgaa-darmstadt-germany-appoints-david-weinreich-as-new-global-head-of-randd-and-chief-medical-officer-for-healthcare-business-sector</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/merck-kgaa-darmstadt-germany-appoints-david-weinreich-as-new-global-head-of-randd-and-chief-medical-officer-for-healthcare-business-sector</guid>
<pubDate>Tue, 02 Sep 2025 12:00:00 GMT</pubDate>
<description>DARMSTADT, Germany, September 02, 2025--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Chief Medical Officer for its Healthcare business sector.</description>
</item>
<item>
<title>Zhejiang-based GNMI Expands Overseas: Hangzhou Becomes a New Starting Point for the China-German Industrial Synergies</title>
<link>https://6ix.com/company/merck-kgaa/news/zhejiang-based-gnmi-expands-overseas-hangzhou-becomes-a-new-starting-point-for-the-china-german-industrial-synergies-1</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/zhejiang-based-gnmi-expands-overseas-hangzhou-becomes-a-new-starting-point-for-the-china-german-industrial-synergies-1</guid>
<pubDate>Mon, 01 Sep 2025 20:00:00 GMT</pubDate>
<description>Hangzhou, China, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Against the backdrop of West Lake, where the reflections of water meet the glow of technology, Global New Material International Holdings Limited (“Global New Material International”) officially completed the acquisition of the global Surface Solutions business (Susonity) from Merck KGaA and inaugurated its Asia-Pacific headquarters in Tonglu, Hangzhou. This €665 million cross-border acquisition is not only the largest cross-border transaction</description>
</item>
<item>
<title>Skyhawk Therapeutics Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders</title>
<link>https://6ix.com/company/merck-kgaa/news/skyhawk-therapeutics-announces-strategic-collaboration-with-merck-kgaa-darmstadt-germany-to-discover-novel-rna-targeting-small-molecules-for-neurological-disorders</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/skyhawk-therapeutics-announces-strategic-collaboration-with-merck-kgaa-darmstadt-germany-to-discover-novel-rna-targeting-small-molecules-for-neurological-disorders</guid>
<pubDate>Mon, 18 Aug 2025 12:00:00 GMT</pubDate>
<description>Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today announces a strategic research collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company. The collaboration will focus on the discovery of novel RNA-targeting small molecules in select neurological indications with high unmet medical need.</description>
</item>
<item>
<title>C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/merck-kgaa/news/c4-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/c4-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Thu, 07 Aug 2025 11:00:00 GMT</pubDate>
<description>Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C Meeting Held With FDA; Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early 2026 Preclinical Milestone Achieved Under the Collaboration With Merck KGaA, Darmstadt, Germany, Which Is</description>
</item>
<item>
<title>MilliporeSigma and Washington University in St. Louis Sign MoU to Advance Scientific Collaboration</title>
<link>https://6ix.com/company/merck-kgaa/news/milliporesigma-and-washington-university-in-st-louis-sign-mou-to-advance-scientific-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/merck-kgaa/news/milliporesigma-and-washington-university-in-st-louis-sign-mou-to-advance-scientific-collaboration</guid>
<pubDate>Thu, 24 Jul 2025 21:00:00 GMT</pubDate>
<description>ST. LOUIS, July 24, 2025--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Washington University (WashU) in St. Louis, Missouri, USA. The agreement marks the next chapter in a nearly century-long partnership dedicated to advancing scientific research and innovation.</description>
</item>
</channel>
</rss>